This next in a series of quick quizzes in dermatology asks -what’s the cause of this itchy, vesicular rash on the hands?

DURHAM, N.C., March 17, 2026 - MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today welcomed the news that its partner, Palvella Therapeutics, Inc. ( ...

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting(OXFORDSHIRE, England & ...

Tenosynovial giant cell tumor is a locally aggressive tumor of the joint synovium, bursae or tendon sheaths. Although rare and not life-threatening, it can cause significant pain, stiffness and joint ...

In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions with the U.S. Food and Drug ...

Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) for 12 monthsRAHWAY, ...

Unexpected chilblains, unusual rashes, and flareups of existing conditions— Katharine Lang asks experts how the skin can react to covid infection “Covid toes”—swollen and itchy red or purple toes, or ...

“We are thrilled to reach this crucial milestone in our clinical program”, said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The results of this Phase 2b study show promising reductions ...

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.